Patients' and Healthcare Professionals' Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey.
Antifibrotics
Idiopathic pulmonary fibrosis
Pill burden
Pirfenidone
Quality of life
Questionnaire
Journal
Pulmonary therapy
ISSN: 2364-1746
Titre abrégé: Pulm Ther
Pays: United States
ID NLM: 101687144
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
15
01
2020
pubmed:
21
3
2020
medline:
21
3
2020
entrez:
21
3
2020
Statut:
ppublish
Résumé
Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating interstitial lung disease. Two antifibrotics, pirfenidone and nintedanib, are available for IPF treatment. Pirfenidone is available as 267 mg capsules and, more recently, as 267 mg and 801 mg tablets. The aim of this study was to examine the perceived benefits of the 801 mg formulation on patient quality of life (QoL), IPF management and pill burden. Forty-seven patients with IPF and 170 healthcare professionals (HCPs; 150 physicians in France, Germany, Spain and the USA and 20 nurses in the USA) completed online questionnaires comprising 67 and 61 questions, respectively. Eligible patients had experience switching from the 267 mg pirfenidone tablet or capsule formulations to the 801 mg tablet formulation, and eligible HCPs were experienced in managing this switch. Questions included single and multiple responses and scalar questions with responses on a 7-point Likert scale. Patients received the 267 mg formulation for a median (range) of 6.0 (2.0-40.0) months prior to switching to the 801 mg formulation. Higher percentages of patients reported satisfaction with the 801 mg versus the 267 mg formulation for its convenience (64 vs. 17%) and number of dosage units (70 vs. 2%). More patients reported good emotional well-being on the 801 mg versus the 267 mg formulation (51 vs. 21%), and fewer patients reported missing a dose of pirfenidone (21 vs. 30%). More HCPs perceived high patient adherence with the 801 mg versus the 267 mg formulation (57 vs. 37%). Overall, 33% of physicians had experienced switching patients back to the 267 mg formulation. Patients and HCPs consistently favoured the 801 mg formulation across multiple domains, including convenience, patient QoL and adherence. The 801 mg formulation may provide an alternative to the 267 mg formulation in patients established on the recommended daily dose of pirfenidone.
Identifiants
pubmed: 32193713
doi: 10.1007/s41030-020-00111-y
pii: 10.1007/s41030-020-00111-y
pmc: PMC7229113
doi:
Types de publication
Journal Article
Langues
eng
Pagination
93-105Références
Kreuter M. Pirfenidone: an update on clinical trial data and insights from everyday practice. Eur Respir Rev. 2014;23:111–7.
doi: 10.1183/09059180.00008513
Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183:431–40.
doi: 10.1164/rccm.201006-0894CI
Duck A, Spencer LG, Bailey S, Leonard C, Ormes J, Caress AL. Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis. J Adv Nurs. 2015;71:1055–65.
doi: 10.1111/jan.12587
van Manen MJ, Geelhoed JJ, Tak NC, Wijsenbeek MS. Optimizing quality of life in patients with idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2017;11:157–69.
doi: 10.1177/1753465816686743
Bonella F, Wijsenbeek M, Molina-Molina M, et al. European IPF patient charter: unmet needs and a call to action for healthcare policymakers. Eur Respir J. 2016;47:597–606.
doi: 10.1183/13993003.01204-2015
European Medicines Agency. Summary of Product Characteristics—Ofev (nintedanib). 2018. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003821/human_med_001834.jsp&mid=WC0b01ac058001d124 . Accessed 30 Aug 2019.
European Medicines Agency. Summary of Product Characteristics—Esbriet (pirfenidone). 2018. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002154/human_med_001417.jsp&mid=WC0b01ac058001d124 . Accessed 30 Aug 2019.
U.S. Food and Drug Administration. Summary review of regulatory action—Esbriet®. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/022535Orig1s000SumR.pdf . Accessed 30 Aug 2019.
Food and Drug Administration. Summary review of regulatory action—Ofev
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47:243–53.
doi: 10.1183/13993003.00026-2015
Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.
doi: 10.1056/NEJMoa1402584
Kreuter M, Bonella F, Wijsenbeek M, Maher TM, Spagnolo P. Pharmacological treatment of idiopathic pulmonary fibrosis: current approaches, unsolved issues, and future perspectives. Biomed Res Int. 2015;2015:329481.
pubmed: 26779535
pmcid: 4686637
Pan L, Belloni P, Ding HT, Wang J, Rubino CM, Putnam WS. A pharmacokinetic bioequivalence study comparing pirfenidone tablet and capsule dosage forms in healthy adult volunteers. Adv Ther. 2017;34:2071–82.
doi: 10.1007/s12325-017-0594-8
Morris H, Marshall T, Zakis K, et al. Introducing a new formulation of pirfenidone to reduce tablet burden for the IPF patient: Is it tolerable? Is it easy to take? What do our patients think? Eur Respir J. 2018;62(Suppl 62):PA4782. https://doi.org/10.1183/13993003.congress-2018.PA4782
European Pharmaceutical Market Research Association (EphMRA). Code of Conduct. 2017. https://www.ephmra.org/media/1785/ephmra-2017-code-of-conduct-october-2017.pdf . Accessed 30 Aug 2019.
Wuyts WA, Dahlqvist C, Slabbynck H, et al. Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. BMJ Open Respir Res. 2018;5:e000331.
doi: 10.1136/bmjresp-2018-000331
Jo HE, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J. 2017;49:1601592.
doi: 10.1183/13993003.01592-2016
Behr J, Kreuter M, Hoeper MM, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J. 2015;46:186–96.
doi: 10.1183/09031936.00217614
World Health Organization. Adherence to long-term therapies: Evidence for action. 2003. http://apps.who.int/iris/bitstream/10665/42682/1/9241545992.pdf . Accessed 30 Aug 2019.
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–310.
doi: 10.1016/S0149-2918(01)80109-0
Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164:722–32.
doi: 10.1001/archinte.164.7.722
Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest. 2006;130:65S–72S.
doi: 10.1378/chest.130.1_suppl.65S
Lindell KO, Olshansky E, Song MK, et al. Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. Heart Lung. 2010;39:304–13.
doi: 10.1016/j.hrtlng.2009.08.005
Mason W, McLaughlin S, Dedopoulos S, et al. Real-world comprehensive disease management of patients with idiopathic pulmonary fibrosis. Current Respir Med Rev. 2019;15:4–15.
doi: 10.2174/1573398X15666190212155051
Russell AM, Ripamonti E, Vancheri C. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients’ perspectives of the disease and treatment. BMC Pulm Med. 2016;16:10.
doi: 10.1186/s12890-016-0171-y